A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

Journal of Experimental Medicine

Volumn 197, Issue 12, 2003, Pages 1667-1676

  Dhodapkar, Madhav V ^a,b   Geller, Matthew D ^a   Chang, David H ^a   Shimizu, Kanako ^a   Fujii, Shin Ichiro ^a   Dhodapkar, Kavita M ^a   Krasovsky, Joseph ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dendritic cells; Immunotherapy; Interferon ; Multiple myeloma; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; GLYCOLIPID; TUMOR DERIVED GLYCOLIPID; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B CELL TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CELL FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; GAMMOPATHY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONPROGRESSIVE MYELOMA; PRECANCER; PREMALIGNANT GAMMOPATHY; PRIORITY JOURNAL; PROGRESSIVE MULTIPLE MYELOMA; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD1; BIOLOGICAL MARKERS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PRECANCEROUS CONDITIONS; T-LYMPHOCYTE SUBSETS;

EID: 0038543513     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021650     Document Type: Article

References (44)

1. Bernards, R., and R.A. Weinberg. 2002. A progression puzzle. Nature. 418:823.
2. Rawstron, A.C., M.J. Green, A. Kuzmicki, B. Kennedy, J.A. Fenton, P.A. Evans, S.J. O'Connor, S.J. Richards, G.J. Morgan, A.S. Jack, and P. Hillmen. 2002. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 100:635-639.
3. Kyle, R.A., and S.V. Rajkumar. 1999. Monoclonal gammopathies of undetermined significance. Hematol. Oncol. Clin. North Am. 13:1181-1202.
4. Tricot, G. 2000. Multiple myeloma and related plasma cell disorders. In Hematology: Principles and Practice. R. Hoffman, editor. Churchill Livingstone, New York. 1398-1415.
5. Fonseca, R., R.J. Bailey, G.J. Ahmann, S.V. Rajkumar, J.D. Hoyer, J.A. Lust, R.A. Kyle, M.A. Gertz, P.R. Greipp, and G.W. Dewald. 2002. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 100:1417-1424.
6. Kuehl, W.M., and P.L. Bergsagel. 2002. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer. 2:175-187.
7. Zhan, F., J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R. Sanderson, Y. Yang, C. Wilson, M. Zangari, et al. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 99:1745-1757.
8. Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111.
9. Smyth, M.J., N.Y. Crowe, and D.I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13:459- 463.
10. Street, S.E., J.A. Trapani, D. MacGregor, and M.J. Smyth. 2002. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196:129-134.
11. Dhodapkar, M.V., J. Krasovsky, and K. Olson. 2002. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells. Proc. Natl. Acad. Sci. USA. 99:13009-13013.
12. Godfrey, D.I., K.J. Hammond, L.D. Poulton, M.J. Smyth, and A.G. Baxter. 2000. NKT cells: facts, functions and fallacies. Immunol. Today. 21:573-583.
13. Benlagha, K., and A. Bendelac. 2000. CD1d-restricted mouse V alpha 14 and human V alpha 24 T cells: lymphocytes of innate immunity. Semin. Immunol. 12:537-542.
14. Park, S.H., and A. Bendelac. 2000. CD1-restricted T-cell responses and microbial infection. Nature. 406:788-792.
15. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 278:1626-1629.
16. Toura, I., T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai, and M. Taniguchi. 1999. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alphagalactosylceramide. J. Immunol. 163:2387-2391.
17. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, et al. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. Natl. Acad. Sci. USA. 95:5690-5693.
18. Metelitsa, L.S., O.V. Naidenko, A. Kant, H.W. Wu, M.J. Loza, B. Perussia, M. Kronenberg, and R.C. Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167:3114-3122.
19. Nakagawa, R., K. Motoki, H. Ueno, R. Iijima, H. Nakamura, E. Kobayashi, A. Shimosaka, and Y. Koezuka. 1998. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KPN7000. Cancer Res. 58:1202-1207.
20. Moodycliffe, A.M., D. Nghiem, G. Clydesdale, and S.E. Ullrich. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1:521-525.
21. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
22. Kawano, T., T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. 1999. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 59:5102-5105.
23. Nieda, M., A. Nicol, Y. Koezuka, A. Kikuchi, T. Takahashi, H. Nakamura, H. Furukawa, T. Yabe, Y. Ishikawa, K. Tadokoro, and T. Juji. 1999. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1-drestricted and Valpha24TCR-mediated manner. Hum. Immunol. 60:10-19.
24. Yanagisawa, K., K. Seino, Y. Ishikawa, M. Nozue, T. Todoroki, and K. Fukao. 2002. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168:6494-6499.
25. Tahir, S.M., O. Cheng, A. Shaulov, Y. Koezuka, G.J. Bubley, S.B. Wilson, S.P. Balk, and M.A. Exley. 2001. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167:4046-4050.
26. Dhodapkar, K., J. Krasovsky, B. Williamson, and M. Dhodapkar. 2002. Anti-tumor monoclonal antibodies enhance cross presentation of cellular antigens and the generation of tumor specific killer T cells by dendritic cells. J. Exp. Med. 195:125-133.
27. Fujii, S.I., K. Shimizu, R.M. Steinman, and M.V. Dhodapkar. 2003. Detection and activation of human V alpha 24+ natural killer T cells using alpha galactosyl ceramide pulsed dendritic cells. J. Immunol. Methods. 272:147-159.
28. Gumperz, J.E., S. Miyake, T. Yamamura, and M.B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625-636.
29. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, and N. Bhardwaj. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:173-180.
30. Sandberg, J.K., N.M. Fast, E.H. Palacios, G. Fennelly, J. Dobroszycki, P. Palumbo, A. Wiznia, R.M. Grant, N. Bhardwaj, M.G. Rosenberg, and D.F. Nixon. 2002. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 76:7528-7534.
31. Exley, M.A., S.M. Tahir, O. Cheng, A. Shaulov, R. Joyce, D. Avigan, R. Sackstein, and S.P. Balk. 2001. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J. Immunol. 167:5531-5534.
32. van der Vliet, H.J., N. Nishi, Y. Koezuka, B.M. von Blomberg, A.J. van den Eertwegh, S.A. Porcelli, H.M. Pinedo, R.J. Scheper, and G. Giaccone. 2001. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. Immunol. Methods. 247:61-72.
33. Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:7556-7561.
34. Crowe, N.Y., M.J. Smyth, and D.I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127.
35. Coughlin, C.M., K.E. Salhany, M.S. Gee, D.C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J.E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFNgamma affect tumorigenicicy and response to IL-12 therapy and antiangiogenesis. Immunity. 9:25-34.
36. Catlett-Falcone, R., T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J.L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105-115.
37. Portier, M., X.G. Zhang, E. Caron, Z.Y. Lu, R. Bataille, and B. Klein. 1993. Gamma-interferon in multiple myeloma: inhibition of interleukin-6 dependent myeloma cell growth and down-regulation of IL-6 receptor expression in vitro. Blood. 81:3076-3082.
38. Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 408:600-605.
39. Fujii, S., K. Shimuzu, M. Kronenberg, and R.M. Steinman. 2002. Prolonged interferon-g producing NKT responses induced with a-galactosyl ceramide loaded dendritic cells. Nat. Immunol. 3:867-874.
40. Sriram, V., S. Cho, P. Li, P.W. O'Donnell, C. Dunn, K. Hayakawa, J.S. Blum, and R.R. Brutkiewicz. 2002. Inhibition of glycolipid shedding rescues recognition of a CD1 + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA. 99:8197-8202.
41. Lee, P.T., K. Benlagha, L. Teyton, and A. Bendelac. 2002. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 195:637-641.
42. Nicol, A., M. Nieda, Y. Koezuka, S. Porcelli, K. Suzuki, K. Tadokoro, S. Durrant, and T. Juji. 2000. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology. 99:229-234.
43. Smyth, M.J., E. Cretney, K. Takeda, R.H. Wiltrout, L.M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:661-670.
44. Nieda, M., A. Nicol, Y. Koezuka, A. Kikuchi, N. Lapteva, Y. Tanaka, K. Tokunaga, K. Suzuki, N. Kayagaki, H. Yagita, et al. 2001. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 97:2067-2074.